Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer

Lior Z Braunstein, Ming-Hui Chen, Marian Loffredo, Philip W Kantoff, Anthony V D'Amico, Lior Z Braunstein, Ming-Hui Chen, Marian Loffredo, Philip W Kantoff, Anthony V D'Amico

Abstract

Background. Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored. Methods. Between 1995 and 2001, 206 men were enrolled in a randomized trial evaluating the survival difference of adding 6 months of ADT to radiation therapy (RT). BMI measurements were available in 171 men comprising the study cohort. The primary endpoint was weight gain of ≥10 lbs by 6-month followup. Logistic regression analysis was performed to assess whether baseline BMI or treatment received was associated with this endpoint adjusting for known prognostic factors. Results. By the 6-month followup, 12 men gained ≥10 lbs, of which 10 (83%) received RT + ADT and, of these, 7 (70%) were obese at randomization. Men treated with RT as compared to RT + ADT were less likely to gain ≥10 lbs (adjusted odds ratio (AOR): 0.18 [95% CI: 0.04-0.89]; P = 0.04), whereas this risk increased with increasing BMI (AOR: 1.15 [95% CI: 1.01-1.31]; P = 0.04). Conclusions. Consideration should be given to avoid ADT in obese men with low- or favorable-intermediate risk PC where improved cancer control has not been observed, but shortened life expectancy from weight gain is expected.

References

    1. Bolla M, Van Tienhoven G, De Reijke T, van den Bergh A, van der Meijden A, Poortmans P, et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—results of the randomized EORTC phase III trial 22961. Journal of Clinical Oncology. 2007;25(supplement 18)
    1. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The Lancet Oncology. 2010;11(11):1066–1073.
    1. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. Journal of the American Medical Association. 2004;292(7):821–827.
    1. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. Journal of Clinical Oncology. 2008;26(15):2497–2504.
    1. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. The New England Journal of Medicine. 2011;365(2):107–118.
    1. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. International Journal of Radiation Oncology Biology Physics. 2001;50(5):1243–1252.
    1. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. International Journal of Radiation Oncology Biology Physics. 2005;61(5):1285–1290.
    1. Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR. Estrogenic side effects of androgen deprivation therapy. Reviews in Urology. 2007;9(4):163–180.
    1. Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Current Opinion in Urology. 2004;14(3):177–183.
    1. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61(2):32–38.
    1. Smith JA., Jr. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate. Journal of Urology. 1994;152(1):132–134.
    1. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist. 2003;8(5):474–487.
    1. Chen AC, Petrylak DP. Complications of androgen deprivation therapy in men with prostate cancer. Current Oncology Reports. 2004;6(3):209–215.
    1. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. Journal of Clinical Endocrinology and Metabolism. 2002;87(2):599–603.
    1. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen, deprivation therapy. Cancer. 2004;100(5):892–899.
    1. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. Journal of Urology. 2002;167(6):2361–2367.
    1. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. American Journal of Epidemiology. 1996;143(9):889–897.
    1. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science. 2003;104(2):195–201.
    1. Oh J-Y, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the rancho bernardo study. Diabetes Care. 2002;25(1):55–60.
    1. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism. 2006;91(4):1305–1308.
    1. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Clinical Endocrinology and Metabolism. 2001;86(9):4261–4267.
    1. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology. 1996;48(5):800–804.
    1. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology. 2006;24(24):3979–3983.
    1. De Gonzalez AB, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. The New England Journal of Medicine. 2010;363(23):2211–2219.
    1. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bulletin. 1945;1(6):80–83.
    1. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. The Annals of Mathematical Statistics. 1947;18(1):50–60.
    1. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. The Challenge of Epidemiology: Issues and Selected Readings. 2004;1(1):533–553.
    1. Cochran WG. Some methods for strengthening the common χ 2 tests. Biometrics. 1954;10(4):417–451.
    1. Edge SB, Compton CC. The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology. 2010;17(6):1471–1474.
    1. Hilbe JM. Logistic Regression Models. Boca Raton, Fla, USA: CRC Press; 2009.
    1. Fisher RA. On the interpretation of χ 2 from contingency tables, and the calculation of P. Journal of the Royal Statistical Society. 1922;85(1):87–94.
    1. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. The New England Journal of Medicine. 2006;355(8):763–778.
    1. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW., Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. The New England Journal of Medicine. 1999;341(15):1097–1105.
    1. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Archives of Internal Medicine. 2002;162(16):1867–1872.
    1. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–880.
    1. Rosengren A, Wedel H, Wilhelmsen L. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. European Heart Journal. 1999;20(4):269–277.
    1. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17(9):961–969.
    1. Lazar MA. How obesity causes diabetes: not a tall tale. Science. 2005;307(5708):373–375.
    1. Meng MV, Elkin EP, Latini DM, DuChane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE) The Journal of Urology. 2005;173(5):1557–1561.
    1. Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J, Martinez A. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. The Journal of Urology. 2002;167(6):2443–2447.
    1. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. Journal of Clinical Oncology. 2000;18(6):1187–1192.
    1. Mohler JL. NCCN clinical practice guidelines in oncology on prostate cancer. Journal of the National Comprehensive Cancer Network. 2010;8(2):p. 145.
    1. Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. European Urology. 2013;64(6):895–902.
    1. D’Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Journal of the American Medical Association. 2008;299(3):289–295.
    1. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. The New England Journal of Medicine. 2008;358(12):1250–1261.
    1. Berg CD, Andriole GL, Crawford ED, et al. Mortality results from a randomized prostate-cancer screening trial. The New England Journal of Medicine. 2009;360(13):1310–1319.
    1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized european study. The New England Journal of Medicine. 2009;360(13):1320–1328.
    1. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. The Lancet Oncology. 2010;11(8):725–732.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner